None listed
Conditions
Interventions
Drug : Intervention group: intravenous vancomycin 15-20 mg/kg q 12 hrs plus intravenous cefazolin 2.0 g iv q 8 hrs
Control group : intravenous vancomycin 15-20 mg/kg q 12 hrs only
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult age over 19 year 2. Confimed MRSA bacteremia 3. Who agree to participate the study
Exclusion criteria
Exclusion criteria: 1. Type 1 hypersensitivity to cefazolin or vancomycin 2. Polymicrobial infection 3. Receiving anti MRSA therapy longer than 72 hours before the study enrollment 4. patient expected to die in the next 48 hour 5. history of MRSA bacteremia within previous 3 months 6. Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 90 days composite outcome with 4 components: (1) all-cause mortality; (2) persistent bacteremia at study day 5; (3) microbiological relapse defined as a positive blood culture for MRSA at least 72 hours after a preceding negative culture; and (4) microbiological treatment failure defined as a positive sterile site culture for MRSA at least 14 days after randomization. | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) all-cause mortality; (2) persistent bacteremia at study day 5; (3) microbiological relapse defined as a positive blood culture for MRSA at least 72 hours after a preceding negative culture; and (4) microbiological treatment failure defined as a positive sterile site culture for MRSA at least 14 days after randomization. | — |
Countries
Korea, Republic of
Contacts
Public ContactYang Soo Kim
Asan Medical Center
Outcome results
None listed